![](https://i0.wp.com/hrnxt.com/wp-content/uploads/2021/05/Esco_Lifesciences_Group_Logo-1.jpg?resize=200%2C112&ssl=1)
Esco Lifesciences (Esco) announced the close of an over-subscribed US$200 million Series A and Crossover round. The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investment Corporation, Singapore-based global investor EDBI, a reputable, long-term institutional investor, and other sophisticated investors. XQ Lin, Chairman and CEO of…